GlassScriptPhysician profile
Kamya Sankar
NPI 1346602836
$2,701.72
in general payments reported to CMS, 2019-2025
10 companies · $2,528 in 2025
The $2,528 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $70.19 · 2024: $104 · 2025: $2,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,460 · Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,460.00 |
| Food and Beverage | $171.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $2,460.00 | 2025 | Tagrisso |
| Galvanize Therapeutics, INC | $103.53 | 2024 | Aliya System |
| Daiichi Sankyo INC. | $70.19 | 2022 | |
| Genentech USA, INC. | $68.00 | 2025 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamya Sankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.